We are live on ! Find out more

SciSparc

SPRC

Market cap $225K

0.3865 USD

-0.0321

7.67%

At close Updated Nov 9, 12:28 PM EST

1 day

-7.67%

5 days

-35.32%

1 month

-91.35%

3 months

-94.15%

6 months

-93.62%

Year to date

-96.93%

1 year

-98.46%

5 years

-100%

10 years

-100%

About: SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

Employees: 3

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 94.7%

Negative 5.3%

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has achieved further progress in its U.S. Food and Drug Administration (“FDA”) approved clinical trial program evaluating SCI-110 for the treatment of Tourette Syndrome (“TS”) in adults.

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications

TEL AVIV, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies.

SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications

SciSparc Shares Halted On Circuit Breaker To The Downside, Stock Now Down -23.69%

� 2025 Benzinga.com. Benzinga does not provide investment advice.

SciSparc Shares Halted On Circuit Breaker To The Downside, Stock Now Down -23.69%

SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies

TEL AVIV, Israel, Oct. 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that it will shift its strategic focus toward Agentic AI-powered technologies, including cybersecurity and finance technologies.

SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies

SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture

TEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, that CliniQuantum Ltd. (“CliniQuantum”), NeuroThera's majority owned subsidiary, reported that its Graphics Processing Unit- accelerated (“GPU”) quantum-simulation platform achieved an approximately 16.8-fold computational acceleration using a single machine with 64 cores (x86_64) and a single NVIDIA T4 Tensor Core GPU compared with the same 64-vCPU machine with only Central Processing Unit (“CPU”) implementation.

SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

The U.S. patent applications cover proprietary combinations of NeuroThera's PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

This strategic engagement is designed to strengthen NeuroThera's U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public ‑ health importance of advancing new treatment options for adult Tourette Syndrome TEL AVIV, Israel – TheNewswire - September 2, 2026 - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced that it is pursuing U.S. Food and Drug Administration (“FDA”) Orphan Drug Designation covering SCI-110, its drug candidate for the treatment adults with Tourette Syndrome (“TS”), a rare condition that may qualify for Orphan Drug Designation.

SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

This strategic engagement is designed to strengthen NeuroThera's U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public ‑ health importance of advancing new treatment options for adult Tourette Syndrome TEL AVIV, Israel – TheNewswire - September 2, 2026 - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced that it is pursuing U.S. Food and Drug Administration (“FDA”) Orphan Drug Designation covering SCI-110, its drug candidate for the treatment adults with Tourette Syndrome (“TS”), a rare condition that may qualify for Orphan Drug Designation.

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, continued advancement in participant enrollment for the clinical trial assessing NeuroThera's innovative SCI-210 treatment for symptoms associated with autism spectrum disorder (“ASD”).

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

Toronto, Ontario, August 31, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced continued advancement in participant enrollment for its clinical trial assessing its innovative SCI-210 treatment for symptoms associated with autism spectrum disorder (“ ASD ”). The clinical trial, conducted at Soroka Medical Center in Israel, is a double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of SCI-210 in children diagnosed with ASD. To date, 26 children have been enrolled, marking strong progress toward the planned total of 60 children between the ages of five and 18, each of whom will receive treatment over a 20-week period.

NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

See News Rankings

Price charts implemented using Lightweight Charts™